Non alcoholic steatohepatitis (NASH) experimental model induction in rats

International Journal of Pharma and Bio Sciences

Volumn 3, Issue 3, 2012, Pages

  Mohan, Surapaneni Krishna ^a   Sarswathi, P ^a   Jainu, Mallika ^b  

^a SAVEETHA MEDICAL COLLEGE AND HOSPITAL   (India)

^b SSN COLLEGE OF ENGINEERING   (India)

Author keywords

Experimental model; Fibrosis; High fat diet; NASH; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; CYTOPLASM; FOOD COMPOSITION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LIPID DIET; LIPID STORAGE; LIVER CELL; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT;

EID: 84867727880     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 128: 1898-1906, (2005).
2. Szczepaniak LS, Nurenberg P, Leonard et al., "Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population," Amer J Phy, 288: E462-E468, (2005).
3. Kim WR, Brown RS, Terrault NA, El-SeraHH Burden of liver disease in the united states: summary of a workshop. Hepatology, 36: 227-242, (2002).
4. Suneel B., Balakrishna D., Sridhar M., Aparna RR and Sowjanya B. Zinc, Copper, C-reactive protein and lipid peroxidation in chronic liver diseases, Int J Pharm. Bio. Sci, 3 (2); April-June, (2012).
5. Matsuzaka T, & Shimano H, Molecular mechanisms involved in hepatic steatosis and insulin resistance. J Diabetes Invest, 2: 170-175, (2011).
6. Shulman AI and Mangelsdorf DJ., "Retinoid X receptor heterodimers in the metabolic syndrome". The New England J of Med, 353: 604-615, (2005).
7. Anitha U and R. Kuppuswamy. Sesame meal administration attenuate the high-fat diet induced lipid abnormalities and improve insulin sensitivity in wistar rats. Int J Phar. Bio. Sci., 2 (4); Oct-Dec: B499-B505, (2011).
8. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol, 2:1048-58, (2004).
9. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 49:306-17, (2009).
10. Satyanand Tyagi and Sachin Kumar. Clinical applications of elastography: an overview. Int J Pharm. Bio. Sci., 1 (3); July-Sep: 1-8, (2010).
11. Rivera L, Moron R, Sanchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity, 16; 2081-2087, (2008).
12. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology, 114:842-845 (1998).
13. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci, 65: 166-176, (2002).
14. Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis, 5: 161-173, (2001).
15. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fi brosis. Hepatology, 39: 273-278, (2004).
16. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116:1413-1419, (1999).
17. Adams LA, Talwalkar JA Diagnostic Evaluation of Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol, 40:S34-S38, (2006).
18. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Longterm follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 44:865-873, (2006).
19. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholicfatty liver disease. Hepatology, 44:27-33, (2006).
20. Lieber CS, Leo MA, Mak KM, et al.Amodel of non-alcoholic fatty liver disease (NAFLD), including steatohepatitis (NASH), in rats fed a high fat Lieber-DeCarli diet. Hepatology, 36:402A, (2002).